
5 Keys to Patient Education on GLP-1 RAs for Weight Loss
As ‘magic’ weight loss drugs capture public attention, you’ve likely
As ‘magic’ weight loss drugs capture public attention, you’ve likely
September 23, 2016 First clinical trial to study GLP-1 receptor
The GLP-1 agonist semaglutide is the latest diabetes therapy to
The GLP-1 receptor agonist lixisenatide has received US FDA approval
Results of the cardiovascular outcomes LEADER trial have shown the
CV outcomes data from the ELIXA trial have been published
The GLP-1 agonist liraglutide has been shown to significantly decrease
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Copyright © 2025, Cardiometabolic Health Congress. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.